CCA
NBIX icon

Catalyst Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Catalyst Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-20
Closed -$33K – 582
2015
Q4 		$33K Hold
20
– – ﹤0.01% 382
2015
Q3 		$17K Buy
+20
New +$967 ﹤0.01% 449

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Capital Advisors's NBIX Position: Q1 2026 in Review

Catalyst Capital Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 7,800 shares — an estimated $1.11M sold.

Catalyst Capital Advisors first reported a position in NBIX in Q4 2025 and held it in 1 quarter. The position peaked at $1.11M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Catalyst Capital Advisors reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Catalyst Capital Advisors sold 7,800 Neurocrine Biosciences shares in Q1 2026, an estimated $1.11M.
  • Catalyst Capital Advisors first reported a position in Neurocrine Biosciences in Q4 2025 and held it in 1 quarter.
  • Catalyst Capital Advisors's Neurocrine Biosciences position peaked at $1.11M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Catalyst Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.